ReviewExperimental & molecular medicine2026
Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chronic liver disease (CLD) poses a major global health challenge, as its progression to cirrhosis and hepatocellular carcinoma significantly contributes to worldwide morbidity and mortality. Mounting evidence has identified the gut microbiota as a critical modulator of CLD progression, primarily via the gut-liver axis. The liver is continuously exposed to gut-derived signals through the portal circulation, while reciprocally secreting bioactive mediators that shape intestinal microbial composition and function. This bidirectional network enables intricate crosstalk between the gut microbiota and the host immune system. In particular, T lymphocytes, the central effectors of adaptive immunity, are tightly regulated by gut microbiota and their metabolites. Conversely, T cells also modulate the gut microbial ecosystem. Herein, we summarize current knowledge on this bidirectional crosstalk, focusing on how gut microbiota shape T cell differentiation, function and plasticity, as well as the reciprocal impact of T cells on the gut microbiota. Furthermore, we evaluate how these interactions influence the development and progression of various CLDs, including autoimmune liver diseases, alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease and viral hepatitis. Finally, we discuss the therapeutic potential of targeting gut microbiota-T cell interactions through immunomodulatory and microbiota-directed strategies to offer novel therapeutic approaches.
Identifiers
42855466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.